ninety-eight patients with previously-treated advanced soft tissue sarcoma , bone sarcoma , or mesothelioma were randomly assigned to one of two intravenous single-agent treatment regimens , either 6-diazo-5-oxo-l-norleucine ( don ; brief infusions of 50 mg/m2/day for 5 consecutive days every 4 weeks ) or aclacinomycin-a ( acm-a , as 30-min infusions of 100 mg/m2 or 85 mg/m2 , administered every 3 weeks ) .
C1261473
soft tissue sarcoma
C0029463
bone